NCT04005586已完成不适用
A Prospective Controlled Multi-Center Clinical Study to Evaluate The Safety and Effectiveness of Performing 0.50 Diopter Astigmatism Correction on the Commercially Available RxSight Light Adjustable Lens (LAL)
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 2
- 主要终点
- Change in Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control Groups
研究概览
简要总结
The primary objective of this study is to evaluate the safety and effectiveness of performing 0.50 D cylinder correction on the RxSight Light Adjustable Lens (LAL) in patients who have undergone implantation with the FDA approved, commercially available LAL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A study eye implanted with the commercially approved LAL that has not undergone any previous LDD treatments
- •A study eye with manifest refraction cylinder of 0.50 D measured by two independent examiners at the Adjustment #1 visit prior to the first light adjustment treatment.
- •Sign a written Informed Consent form and be willing to receive light treatment for their 0.50 D of cylinder.
- •Between the ages of 40 and 80 inclusive on the day the informed consent form is signed.
- •Good vision in the fellow eye with best corrected distance visual acuity (BCDVA) 20/40 or better.
- •Willing and able to comply with the requirements for study specific procedures and visits
排除标准
- •Pre-existing macular disease in the study eye.
- •History of uveitis in the study eye.
- •Has undergone previous corneal or intraocular surgery in the study eye, except for the cataract surgery and eyes with previous pterygium excision are permitted as long as the pterygium did not extend more than 2mm onto the cornea from the limbus.
- •Subjects taking systemic medication that may increase sensitivity to UV light.
- •Subjects taking a systemic medication that is considered toxic to the retina such as tamoxifen.
- •History of ocular herpes simplex virus in the study eye.
- •Subject who has participated within another ophthalmic clinical trial within the last 3 months.
- •Sutures used at the time of surgery to close the incision wound in the study eye
研究组 & 干预措施
Light Delivery Device (LDD)
Experimental
Patient's study eye will undergo light delivery treatments to the commercially available light adjustable lens.
干预措施: Light Delivery Device (LDD) (Device)
结局指标
主要结局
Change in Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control Groups
时间窗: Post Op Month 3
Mean Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control Groups
时间窗: Post Op Month 3
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Treatment for Stress and Mixed Urinary Incontinence and Vaginal Vault ProlapseMixed IncontinenceUrinary Incontinence, StressVaginal Vault ProlapseNCT00223106Medtronic - MITG467
已完成
3 期
Study Utilizing Rilonacept in Gout ExacerbationsAcute Gout FlareNCT00855920Regeneron Pharmaceuticals225
已完成
3 期
Safety and Effectiveness Study of the TOPS System, a Total Posterior Arthroplasty Implant Designed to Alleviate Pain Resulting From Moderate to Severe Lumbar StenosisLow Back PainLeg PainLumbar Spinal StenosisSpondylolisthesisNCT00405691Impliant, Ltd.450
进行中（未招募）
不适用
RHEIA (Randomized researcH in womEn All Comers With Aortic Stenosis)Heart Valve DiseasesAortic Valve StenosisNCT04160130Optimapharm432
招募中
2 期
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp SystemCardiogenic ShockHeart FailureCongenital Heart DiseaseCardiomyopathiesNCT06080074Stanford University50